S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer
This phase II trial on the assumption that S-1 combined with Leucovorin may have better efficacy and safety than simplified 5-FU/LV infusion therapy in elderly patients with advanced colorectal cancer.
Colorectal Cancer
DRUG: S-1, Leucovorin|DRUG: leucovorin, 5-fluorouracil
response rate, six weeks
progression free survival, six weeks|disease control rate, six weeks|time to treatment failure, six weeks|overall survival, three months|quality of life, six weeks|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, six weeks
This is a randomized phase â…¡ study, in which S-1 is used in combination with leucovorin in elderly patients with advanced colorectal cancer as first-line treatment,comparing with sLV5FU2 therapy. The aim of this study is to determine the efficacy and safety of S-1/LV in elderly patients in the first-line setting. The other secondary endpoints are progression free survival,overall survival, and quality of life are also evaluated.